Abstract
Biotechnology Law ReportVol. 33, No. 2 Symposium on MyriadIn AMP v. Myriad, the Supreme Court Provides an Analytical Framework for Patent Eligibility of Product Claims That Is Different from That for Method ClaimsDebora Plehn-Dujowich and Roy P. IssacDebora Plehn-DujowichSearch for more papers by this author and Roy P. IssacSearch for more papers by this authorPublished Online:16 Apr 2014https://doi.org/10.1089/blr.2014.9987AboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 33Issue 2Apr 2014 InformationCopyright 2014, Mary Ann Liebert, Inc.To cite this article:Debora Plehn-Dujowich and Roy P. Issac.In AMP v. Myriad, the Supreme Court Provides an Analytical Framework for Patent Eligibility of Product Claims That Is Different from That for Method Claims.Biotechnology Law Report.Apr 2014.81-89.http://doi.org/10.1089/blr.2014.9987Published in Volume: 33 Issue 2: April 16, 2014PDF download
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
